The EEA1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function analysis of the EEA1 gene in a human colorectal adenocarcinoma background. This product is generated through CRISPR/Cas9-mediated disruption of the target gene, enabling researchers to investigate the functional consequences of EEA1 ablation in a mixed population of edited cells. The polyclonal format provides a comprehensive representation of genetic heterogeneity, suitable for pooled functional studies without the limitations of clonal selection. This knockout model serves as a versatile tool for examining endocytic trafficking, receptor sorting, and associated signaling pathways in epithelial cancer cells.
The host cell line, HT29, is a well-characterized human colorectal adenocarcinoma cell line originally established from a primary colon tumor. HT29 cells exhibit an epithelial morphology and are widely employed as a model system for studying intestinal epithelial biology, colorectal cancer progression, and mucosal drug delivery. Their robust growth characteristics and predictable in vitro behavior make them a reliable platform for genetic manipulation and downstream phenotypic assays. The HT29 background provides a physiologically relevant context for evaluating the role of endosomal trafficking in colorectal cancer cell function, including cell proliferation, migration, and response to therapeutic agents.
EEA1 (Early Endosome Antigen 1) is a Rab5 GTPase effector and phosphatidylinositol 3-phosphate (PI3P)-binding protein that plays a central role in early endosome tethering and membrane fusion. Through its interaction with Rab5 and PI3P, EEA1 recruits SNARE proteins such as syntaxin-6 and syntaxin-13 to facilitate homotypic endosome fusion and endosomal maturation. This activity is critical for the sorting and trafficking of internalized cargo, including growth factor receptors like EGFR, to lysosomes for degradation or to the plasma membrane for recycling. EEA1 functions downstream of the VPS34/PI3K lipid kinase complex and is a key node connecting endosomal dynamics to PI3K/AKT signaling and autophagy regulation. Disruption of EEA1 leads to impaired endosomal tethering, delayed cargo processing, and altered downstream signaling cascades.
In the HT29 colorectal cancer model, EEA1 knockout provides a powerful system to dissect the contribution of endocytic pathways to cancer cell behavior. HT29 cells rely on intact endosomal trafficking for nutrient uptake, receptor signaling, and maintenance of cell polarity. Loss of EEA1 disrupts early endosome function, which can affect the internalization and degradation of key receptors, thereby modulating proliferative and survival signals. This model is particularly relevant for investigating how endosomal sorting impacts the PI3K/AKT pathway, which is frequently dysregulated in colorectal cancer. Moreover, it enables exploration of the interplay between endocytosis and autophagy, offering insights into therapeutic vulnerabilities in cancer cells.
Research applications for the EEA1 Knockout HT29 Polyclonal Cells span endocytosis and receptor trafficking studies, colorectal cancer signaling analysis, autophagy regulation, and vesicle transport dynamics. The polyclonal population is well-suited for high-content imaging, biochemical assays, and functional genomics screens. Representative assays include EGFR internalization and transferrin uptake assays to monitor endocytic activity, immunofluorescence and co-immunoprecipitation to assess protein interactions and localization, and Western blotting to evaluate pathway activation. These cells can also be used for drug response screening to identify compounds that target endosomal trafficking dependencies in cancer. For further information or technical support, please contact Ascent Research.
